Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Bispecific CAR T-Cells Yield High Response Rate in Relapsed/Refractory Myeloma

Publish date:: December 7, 2019

Key clinical point: A chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) and CD38 had a high overall response rate, long response duration, and manageable safety in patients with relapsed or refractory multiple myeloma

Major finding: The overall response rate was about 90% and 9-month progression free survival rate was approximately 79% as of this report. Grade 3 or greater cytokine release syndrome occurred in about 23%, with no cases of neurotoxicity observed.

Study details: Updated results from a phase 1 dose-escalation trial including 22 patients who had received at least two prior lines of therapy.

Disclosures: One study author was affiliated with Cellyan Therapeutics, Wuhan, China. Dr. Hu and coauthors reported that they had no conflicts of interest to declare.

Citation:

Li C et al. ASH 2019, Abstract 930.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Immuno-oncology

Bispecific CAR T-Cells Yield High Response Rate in Relapsed/Refractory Myeloma,